Aytu biopharma reports fiscal 2025 first quarter operational and financial results

Net income of $1.5 million adjusted ebitda1 of $1.9 million adhd portfolio net revenue up 1% to $15.3 million pediatric portfolio net revenue up 54% sequentially $20.1 million cash balance at september 30, 2024 organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow ryan selhorn promoted to chief financial officer company to host conference call and webcast today, november 13, 2024, at 4:30 p.m. eastern time denver, co / accesswire / november 13, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 first quarter.
AYTU Ratings Summary
AYTU Quant Ranking